Ryan C. Lynch, MD

Seattle Cancer Care Alliance
Assistant Professor
University of Washington School of Medicine
Assistant Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Oncology
“It’s an honor to help guide patients through their medical problems.”
— Dr. Lynch
Why do you practice oncology?

Before I started medical school, I had the opportunity to work in a research lab that studied the development of blood vessels in tumors. Many of the lab’s ongoing projects were being translated into novel therapeutics. Becoming an oncologist was a way I could help bring those therapies to patients. As my training progressed, I worked in oncology clinics and witnessed the translation from bench to bedside firsthand. That experience inspired me to work directly with patients while also exploring novel treatments for lymphomas and chronic lymphocytic leukemia through clinical trials. 

What is your approach to care and treatment?

Every person handles their cancer diagnosis differently; it can set off a wide range of feelings and life changes that are unique to each individual. I enjoy connecting with patients and families, learning about your goals for care, your hopes, your plans for the future and your concerns. It is my job to help you understand and feel comfortable with your treatment plan, whether you’re receiving a standard therapy, choosing a novel approach or participating in a clinical trial. 

Provider background

Specialty: Medical Oncology

Lymphomas, chronic lymphocytic leukemia

I am a board-certified hematologist-oncologist who specializes in caring for patients with lymphomas and chronic lymphocytic leukemia (CLL). I am also involved in clinical research for these diseases. While many excellent therapies are available for CLL and lymphomas, they don’t work for every patient. I conduct clinical trials to optimize treatments and bring novel therapeutic agents to the clinic.  

Diseases treated

Education, experience and certifications
Undergraduate Degree
Harvard University
Medical Degree
Boston University School of Medicine
Washington University, Saint Louis
Stanford University, Hematology-Oncology
Board Certification
Medical Oncology, 2017; Hematology, 2017; Internal Medicine, 2013, American Board of Internal Medicine


Seeking a breakthrough in DLBCL combination therapies 
Seeking a breakthrough in DLBCL combination therapies 

Combining chemotherapy with targeted medicines can cure diffuse large B-cell lymphoma (DLBCL), but cure rates have been stagnant for more than 10 years. That’s why Seattle Cancer Care Alliance (SCCA) is leading research and clinical trials that aim to bring cures to a larger percentage of patients with DLBCL.   


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Complete title
Retrospective Review of Outcomes of Elderly Patients with relapsed/refractory DLBCL treated with Standard-of-Care CAR T-Cell Therapy
Study ID:
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Complete title
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Study ID:
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Complete title
A Phase II Trial of Umbralisib and Pembrolizumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.


SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

Novel Dose-Dense Multidrug Regimen Shows Promise in Relapsed/Refractory Hodgkin Lymphoma

SCCA’s Dr. Ryan Lynch was quoted in a Reuters Health story about results of the first prospective clinical trial of combination immunotherapy in angiosarcoma.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers